Patents by Inventor Carlos Lamas-Peteira

Carlos Lamas-Peteira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8778946
    Abstract: The invention provides certain 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds, particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I).
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: July 15, 2014
    Assignee: Eli Lilly and Company
    Inventors: Carlos Lamas-Peteira, Simon James Richards, Selma Sapmaz, Magnus Wilhelm Walter
  • Publication number: 20130225602
    Abstract: The invention provides certain 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds, particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I).
    Type: Application
    Filed: November 17, 2011
    Publication date: August 29, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Carlos Lamas-Peteira, Simon James Richards, Selma Sapmaz, Magnus Wilhelm Walter
  • Patent number: 7595315
    Abstract: Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: September 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Peter Thaddeus Gallagher, Carlos Lamas-Peteira, Francisco Javier Agejas-Chicharro
  • Patent number: 7354920
    Abstract: Compounds of formula (I) wherein Rx is H; Ry is H or C1-C4 alkyl; each Rz is independently H or C1-C4 alkyl; X represents O; Y represents OH or OR; R is C1-C4 alkyl; and Ar1 and Ar2 are optionally substituted phenyl or 5- or 6-membered heteroaryl rings are selective inhibitors of the reuptake of norepinephrine.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: April 8, 2008
    Assignee: Eli Lilly and Company
    Inventors: Manuel Javier Cases-Thomas, Helen Louise Haughton, Robin George Simmonds, Hélène Catherine Eugénie Rudyk, Magnus Wilhelm Walter, Sivi Ouwerkerk-Mahadevan, John Joseph Masters, Carlos Lamas-Peteira
  • Patent number: 7335660
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: February 26, 2008
    Assignee: Eli Lilly and Company
    Inventors: Javier Agejas-Chicharro, Graham Henry Timms, Andrew Caerwyn Williams, Nicholas Paul Camp, Jeremy Gilmore, Ana Belen Bueno Melendo, Carlos Lamas-Peteira
  • Publication number: 20070276138
    Abstract: Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R1 and W. R1 is —(CH2)n—CH(OR2)—(CH2)mE, —(CH)?C(OR2)—(CH2)mE, —(CH2)n—CH(Y)—(CH2)mE or —(CH)?C(Y)—(CH2)mE; wherein E is COOR3, C1-C3-alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C1-C6 alkyl, haloalkyl and aryl-C0-4-alkyl; R2 is —H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR4, —COOR4, —CONR5R6, —C(S)R4, —C(S)OR4 or —C(S)NR5R6.
    Type: Application
    Filed: December 11, 2006
    Publication date: November 29, 2007
    Inventors: Dawn Brooks, Alan Warshawsky, Chahrzad Montrose-Rafezadeh, Anne Reifel-Miller, Lourdes Prieto, Isabel Rojo, Jose Martin, Maria Gonzales Garcia, Alicia Torrado, Rafael Crespo, Carlos Lamas-Peteira, Robert Ardecky, Maria Finger
  • Patent number: 7192982
    Abstract: Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: March 20, 2007
    Assignees: Ligand Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Dawn Alisa Brooks, Alan M. Warshawsky, Chahrzad Montrose-Rafezadeh, Anne-Reifel Miller, Lourdes Prieto, Isabel Rojo, Jose Alfredo Martin, Maria Rosario Gonzales Garcia, Alicia Torrado, Rafael Ferritto Crespo, Carlos Lamas-Peteira, Robert J. Ardecky, Maria Martin-Ortega Finger
  • Publication number: 20070060585
    Abstract: Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.
    Type: Application
    Filed: December 10, 2004
    Publication date: March 15, 2007
    Inventors: Peter Gallagher, Carlos Lamas-Peteira, Francisco Agejas-Chicharro
  • Publication number: 20050020684
    Abstract: Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length.
    Type: Application
    Filed: May 30, 2002
    Publication date: January 27, 2005
    Inventors: Dawn Brooks, Alan Warshawsky, Chahrzad Montrose-Rafezadeh, Anne-Reifel Miller, Lourdes Prieto, Isabel Rojo, Jose Alfredo Martin, Maria Rosario Gonzales Garcia, Alicia Torrado, Rafael Crespo, Carlos Lamas-Peteira, Robert Ardecky, Maria Martin-Ortega Finger
  • Patent number: 6846830
    Abstract: Use of compounds of the formula (I) where A, E, R1, R2, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: January 25, 2005
    Assignee: Eli Lilly and Company
    Inventors: Stephen Richard Baker, David Bleakman, Carlos Lamas-Peteira
  • Publication number: 20050014750
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals.
    Type: Application
    Filed: December 6, 2002
    Publication date: January 20, 2005
    Inventors: Javier Agejas-Chicharro, Graham Timms, Andrew Williams, Nicholas Camp, Jeremy Gilmore, Ana Bueno Melendo, Carlos Lamas-Peteira
  • Publication number: 20040180883
    Abstract: This invention relates to compounds of formula (I) wherein R2 to R10, —X—Y—, A, —W—, n and p have the values defined in claim 1, their preparation and use as pharmaceuticals.
    Type: Application
    Filed: December 12, 2003
    Publication date: September 16, 2004
    Inventors: Jeremy Gilmore, Carlos Lamas-Peteira, Maria Alicia Torrado Varela
  • Publication number: 20040122001
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.
    Type: Application
    Filed: January 16, 2004
    Publication date: June 24, 2004
    Inventors: Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Nicholas Paul Camp, Jeremy Gilmore, Alma Maria Jimenez-Aguado, Carlos Lamas-Peteira, Alicia Marcos-Llorente, Michael Philip Mazanetz, Carlos Montero Salgado, Graham Henry Timms, Andrew Caerwyn Williams
  • Publication number: 20030073725
    Abstract: Use of compounds of the formula (I) where A, E, R1, R2, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.
    Type: Application
    Filed: September 16, 2002
    Publication date: April 17, 2003
    Inventors: Stephen Richard Baker, David Bleakman, Carlos Lamas-Peteira
  • Patent number: 5869691
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: February 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
  • Patent number: 5861410
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: January 19, 1999
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
  • Patent number: 5861409
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: January 19, 1999
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
  • Patent number: 5861408
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: January 19, 1999
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
  • Patent number: 5663178
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: September 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
  • Patent number: 5643916
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: July 1, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero